Sotio

SOTIO is currently developing and testing multiple oncology products at different stages of preclinical and clinical development.^[7]

SOTIO is developing SOT201, an immunocytokine fusing a proprietary IL-15 superagonist to an anti-PD-1 antibody. As a PD-1-targeted and cis-acting attenuated IL-15 agonist, SOT201 is designed to preferentially activate PD-1+CD8+ T cells, inducing superior anti-tumor effects and reinvigorating exhausted CD8+ T cells in PD-1 sensitive and resistant tumors. SOT201 entered the clinic in May 2024 with the Phase 1 VICTORIA-01 clinical trial.^[8]

SOTIO is advancing a pipeline of antibody-drug conjugates (ADCs) to treat solid tumors through collaborations with Biocytogen, Synaffix, LigaChem, and NBE-Therapeutics.^[9][10] Its two most advanced ADC therapeutic candidates are SOT109, an anti-CDH17 ADC in development for the treatment of colorectal cancer, and SOT106, an anti-LRRC15 ADC in development for the treatment of LRRC15+ sarcomas and other solid tumors.^[11]

SOTIO has its own scientific research and development and also collaborates with other partners. In recent years, SOTIO and PPF have focused also on investing in biotechnology companies developing innovative anticancer treatments in Europe and the US.

At the end of 2020, PPF sold its stake in NBE-Therapeutics, a company developing innovative ADC products for the treatment of solid tumours, to the leading global pharmaceutical company Boehringer Ingelheim. This deal, the largest of its kind to be witnessed in Europe in ten years, showed the value of the ADCs that SOTIO maintains in its portfolio and that it continues to develop.

SOTIO is also managing PPF's investments in biotechnology companies Autolus Therapeutics and Cellestia Biotech.^[12]